Immutep Limited (NASDAQ:IMMP) Short Interest Update

Immutep Limited (NASDAQ:IMMP - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 1,260,000 shares, an increase of 10.5% from the March 15th total of 1,140,000 shares. Based on an average daily volume of 141,400 shares, the days-to-cover ratio is presently 8.9 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IMMP. BNP Paribas Financial Markets raised its holdings in shares of Immutep by 27.8% in the fourth quarter. BNP Paribas Financial Markets now owns 30,600 shares of the biotechnology company's stock valued at $73,000 after acquiring an additional 6,665 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Immutep by 18.2% in the third quarter. Dimensional Fund Advisors LP now owns 68,386 shares of the biotechnology company's stock worth $106,000 after purchasing an additional 10,551 shares in the last quarter. Meridian Wealth Management LLC raised its holdings in Immutep by 3.6% in the fourth quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company's stock worth $774,000 after purchasing an additional 11,250 shares in the last quarter. Virtu Financial LLC bought a new position in Immutep in the fourth quarter worth about $29,000. Finally, Bank of America Corp DE raised its holdings in Immutep by 225.4% in the first quarter. Bank of America Corp DE now owns 31,390 shares of the biotechnology company's stock worth $86,000 after purchasing an additional 21,743 shares in the last quarter. 2.32% of the stock is owned by hedge funds and other institutional investors.

Immutep Stock Down 7.2 %

NASDAQ IMMP traded down $0.18 on Monday, hitting $2.31. 219,586 shares of the stock were exchanged, compared to its average volume of 139,879. The stock has a fifty day moving average price of $2.44 and a two-hundred day moving average price of $2.20. Immutep has a 52-week low of $1.50 and a 52-week high of $3.90.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.